The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Open accessAbstract
Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
On the Absorption of Fluids from the Connective Tissue Spaces
Starling, E. H. (1896) · The Journal of Physiology · doi:10.1113/jphysiol.1896.sp000596 · Cited by 2,148
Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Complex Phenotype of Mice Lacking Occludin, a Component of Tight Junction Strands
Saitou, M., Furuse, M., Sasaki, H., Schulzke, J.-D., Fromm, M., Takano, H., Noda, T., & Tsukita, S. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4131 · Cited by 1,195
Endothelial cell–cell junctions: happy together
Dejana, E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1357 · Cited by 1,188
Applications of next-generation sequencing technologies in functional genomics
Morozova, O., & Marra, M. A. (2008) · Genomics · doi:10.1016/j.ygeno.2008.07.001 · Cited by 1,188
The emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationManagement of adult patients with ascites due to cirrhosis: An update†‡§
Runyon, B. A. (2009) · Hepatology · doi:10.1002/hep.22853 · Cited by 975
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Rl, D., Ce, M., Bungay, P. M., & Vt, D. (1978) · PubMed · Cited by 735
Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.13.1853 · Cited by 715
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Runyon, B. A., Montano, A. A., Akriviadis, E. A., Antillon, M. R., Irving, M. A., & McHutchison, J. G. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-215 · Cited by 651
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549
Mechanisms of transcoelomic metastasis in ovarian cancer
Tan, D. S., Agarwal, R., & Kaye, S. B. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70939-1 · Cited by 520
Self-citationBeyond chemotherapy: targeted therapies in ovarian cancer
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2583 · Cited by 495
Self-citationMesothelial cells: Their structure, function and role in serosal repair
MUTSAERS, S. E. (2002) · Respirology · doi:10.1046/j.1440-1843.2002.00404.x · Cited by 430
Gubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Plüddemann, A., Charles, K., Gordon, S., & Balkwill, F. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5023 · Cited by 411
Runyon, B. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402033300508 · Cited by 400
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Kulbe, H., Thompson, R., Wilson, J. L., Robinson, S., Hagemann, T., Fatah, R., Gould, D., Ayhan, A., & Balkwill, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2941 · Cited by 386
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
Ayantunde, A. A., & Parsons, S. L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl499 · Cited by 385
Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice
Yoneda, J., Kuniyasu, H., Price, J. E., Bucana, C. D., Fidler, I. J., & Crispens, M. A. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.447 · Cited by 375
Huang, S., Robinson, J. B., DeGuzman, A., Bucana, C. D., & Fidler, I. J. (2000) · PubMed · Cited by 369
Mutsaers, S. E. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00242-5 · Cited by 368
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Role of vascular endothelial growth factor in ovarian physiology and pathology
Geva, E., & Jaffe, R. B. (2000) · Fertility and Sterility · doi:10.1016/s0015-0282(00)00670-1 · Cited by 356
Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine
Nilsson, M. B., Langley, R. R., & Fidler, I. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0623 · Cited by 349
Malignant ascites: Systematic review and guideline for treatment
Becker, G., Galandi, D., & Blum, H. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.018 · Cited by 349
Peritoneo-Venous Shunting for Ascites
LEVEEN, H. H., CHRISTOUDIAS, G., IP, M., LUFT, R., FALK, G., & GROSBERG, S. (1974) · Annals of Surgery · doi:10.1097/00000658-197410000-00023 · Cited by 344
Belotti, D., Paganoni, P., Manenti, L., Garofalo, A., Marchini, S., Taraboletti, G., & Giavazzi, R. (2003) · PubMed · Cited by 318
Byrne, A. T., Ross, L. H., Holash, J., Nakanishi, M., Hu, L., Hofmann, J., Yancopoulos, G. D., & Jaffe, R. B. (2003) · PubMed · Cited by 310
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
Hu, L., McArthur, C., & Jaffe, R. B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605626 · Cited by 296
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomsky, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 270
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites
Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., & Ellis, L. M. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0373-0 · Cited by 254
Hu, Y.-L., Tee, M.-K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., & Jaffe, R. B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.762 · Cited by 246
Latifi, A., Luwor, R. B., Bilandzic, M., Nazaretian, S., Stenvers, K., Pyman, J., Zhu, H., Thompson, E. W., Quinn, M. A., Findlay, J. K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046858 · Cited by 240
Gupta, R. A., Tejada, L. V., Tong, B. J., Das, S., Morrow, J. D., Dey, S. K., & DuBois, R. N. (2003) · PubMed · Cited by 220
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Gubbels, J. A., Felder, M., Horibata, S., Belisle, J. A., Kapur, A., Holden, H., Petrie, S., Migneault, M., Rancourt, C., Connor, J. P., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-11 · Cited by 209
Malignant Ascites: Clinical and Experimental Observations
GARRISON, R. N., KAELIN, L. D., HEUSER, L. S., & GALLOWAY, R. H. (1986) · Annals of Surgery · doi:10.1097/00000658-198606000-00009 · Cited by 208
Liu, L.-Z., Hu, X.-W., Xia, C., He, J., Zhou, Q., Shi, X., Fang, J., & Jiang, B.-H. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.08.003 · Cited by 205
Rizzo, S., Hersey, J. M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., Luk, L., Titley, I., Carden, C. P., Box, G., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0788 · Cited by 204
Self-citationThe Accuracy of the Physical Examination in the Diagnosis of Suspected Ascites
Cattau, E. L. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320330060027 · Cited by 196
du Bois, A., Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J.-C., Kuhn, W., Orfeuvre, H., Wagner, U., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2938 · Cited by 196
Penson, R. T., Kronish, K., Duan, Z., Feller, A. J., Stark, P., Cook, S. E., Duska, L. R., Fuller, A. F., Goodman, A. K., Nikrui, N., et al. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.00003.x · Cited by 192
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells
Fang, X., Yu, S., Bast, R. C., Liu, S., Xu, H.-J., Hu, S.-X., LaPushin, R., Claret, F. X., Aggarwal, B. B., Lu, Y., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306662200 · Cited by 192
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
Lane, D., Matte, I., Rancourt, C., & Piché, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-210 · Cited by 190
Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma
Salani, D., Di Castro, V., Nicotra, M. R., Rosanò, L., Tecce, R., Venuti, A., Natali, P. G., & Bagnato, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64791-8 · Cited by 189
Profiling of cytokines in human epithelial ovarian cancer ascites.
Matte, I., Lane, D. A., Laplante, C., Rancourt, C., & Piché, A. (2012) · Europe PMC (PubMed Central) · Cited by 188
Malignant ascites: pathophysiology and treatment
Cavazzoni, E., Bugiantella, W., Graziosi, L., Franceschini, M. S., & Donini, A. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0396-6 · Cited by 175
Clinical and Experimental Observations
Koff, S. A. (1990) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00886-7 · Cited by 167
Shepherd, T. G., Thériault, B. L., Campbell, E. J., & Nachtigal, M. W. (2006) · Nature Protocols · doi:10.1038/nprot.2006.328 · Cited by 161
De Placido, S., Scambia, G., Di Vagno, G., Naglieri, E., Lombardi, A. V., Biamonte, R., Marinaccio, M., Cartenì, G., Manzione, L., Febbraro, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.088 · Cited by 161
Cell–cell and cell–matrix dynamics in intraperitoneal cancer metastasis
Sodek, K. L., Murphy, K., Brown, T. J., & Ringuette, M. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9351-2 · Cited by 159
Puiffe, M., Page, C. L., Filali-Mouhim, A., Zietarska, M., Ouellet, V., Tonin, P. N., Chevrette, M., Provencher, D. M., & Mes‐Masson, A. (2007) · Neoplasia · doi:10.1593/neo.07472 · Cited by 153
Gotlieb, W. H., Amant, F. C., Advani, S. H., Goswami, C., Hirte, H. W., Provencher, D. M., Somani, N., Yamada, S., Tamby, J., & Vergote, I. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70338-2 · Cited by 151
Some consequences of capillary permeability to macromolecules: Starling's hypothesis reconsidered
Renkin, E. M. (1986) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1986.250.5.h706 · Cited by 148
Kassim, S. K., El-Salahy, E. M., Fayed, S. T., Helal, S. A., Helal, T., Azzam, E. E.-D., & Khalifa, A. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.01.014 · Cited by 144
Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams, V. M., Chavez, S. L., Kamsteeg, M., Hanczaruk, B., Schwartz, P. E., Rutherford, T., & Mor, G. (2003) · PubMed · Cited by 139
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites.
Milliken, D., Scotton, C. J., Raju, S., Balkwill, F. R., & Wilson, J. L. (2002) · PubMed · Cited by 136
The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma.
Feldman, G. B., KNAPP, R. C., Order, S. E., & Hellmän, S. (1972) · PubMed · Cited by 133
Rosen, D. G., Mercado‐Uribe, I., Yang, G. S., Bast, R. C., Amin, H. M., Lai, R. L., & Liu, J. (2006) · Cancer · doi:10.1002/cncr.22293 · Cited by 133
Ascitic complement system in ovarian cancer
Bjørge, L., Hakulinen, J., Vintermyr, O., Jarva, H., Jensen, T. S., Iversen, O. E., & Meri, S. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602334 · Cited by 133
Meirelles, K., Benedict, L. A., Dombkowski, D., Pépin, D., Preffer, F. I., Teixeira, J. M., Tanwar, P. S., Young, R. H., MacLaughlin, D. T., Donahoe, P. K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120733109 · Cited by 128
Ströbel, T., Swanson, L., & Cannistra, S. A. (1997) · PubMed · Cited by 123
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
Numnum, T. M., Rocconi, R. P., Whitworth, J. M., & Barnes, M. N. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.018 · Cited by 123
The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-α Antitumor Effects
Moserle, L., Indraccolo, S., Ghisi, M., Frasson, C., Fortunato, E., Canevari, S., Miotti, S., Tosello, V., Zamarchi, R., Corradin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6341 · Cited by 123
Tumor-associated macrophages: a molecular perspective
Sica, A., Saccani, A., & Mantovani, A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00064-4 · Cited by 123
EphA2 overexpression is associated with angiogenesis in ovarian cancer
Lin, Y. G., Han, L. Y., Kamat, A. A., Merritt, W. M., Landen, C. N., Deavers, M. T., Fletcher, M. S., Urbauer, D. L., Kinch, M. S., & Sood, A. K. (2006) · Cancer · doi:10.1002/cncr.22415 · Cited by 122
Malignant ascites: a 2-year review from a teaching hospital
Parsons, S. L., Lang, M. W., & Steele, R. J. (1996) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(96)80009-6 · Cited by 117
Alberti, C., Pinciroli, P., Valeri, B., Ferri, R., Ditto, A., Umezawa, K., Sensi, M., Canevari, S., & Tomassetti, A. (2011) · Oncogene · doi:10.1038/onc.2011.572 · Cited by 115
Ostrowski, M. J. (1986) · Cancer · Cited by 112
Beattie, G. J., & Smyth, J. F. (1998) · PubMed · Cited by 111
Lane, D. A., Goncharenko-Khaider, N., Rancourt, C., & Piché, A. (2010) · Oncogene · doi:10.1038/onc.2010.107 · Cited by 111
Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer
Wang, E., Ngalame, Y., Panelli, M. C., Nguyen-Jackson, H. T., Deavers, M. T., Mueller, P., Hu, W., Savary, C. A., Kobayashi, R., Freedman, R. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.113.11.1 · Cited by 111
Secretion of vascular endothelial growth factor in ovarian cancer.
Santin, A. D., Hermonat, P. L., Ravaggi, A., et al. (1999) · PubMed · Cited by 108
Fleming, N. D., Secord, A. A., von Gruenigen, V., et al. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2008.09.008 · Cited by 106
Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer
Guo, Y., Nemeth, J. A., O'Brien, C. W., Susa, M., Liu, X., Zhang, Z., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1095 · Cited by 106
Obata, N. H., Tamakoshi, K., Shibata, K., Kikkawa, F., & Tomoda, Y. (1997) · PubMed · Cited by 105
Angiogenic protein expression in advanced epithelial ovarian cancer.
Barton, D. P. J., Cai, A., Wendt, K., Young, M. R., Gamero, A. M., & Cesare, S. D. (1997) · PubMed · Cited by 103
Lane, D. A., Robert, V., Grondin, R., Rancourt, C., & Piché, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22840 · Cited by 97
Bamias, A., Koutsoukou, V., Terpos, E., Tsiatas, M. L., Liakos, C., Tsitsilonis, O., Rodolakis, A., Voulgaris, Z., Vlachos, G. D., Papageorgiou, T., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.018 · Cited by 97
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer
Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M. D., Clarke, P. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0996 · Cited by 96
Self-citationColombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L. A., Buzenet, G., & Chamberlain, D. H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.11.021 · Cited by 94
Gardner, M. J., Catterall, J., Jones, L. M., & Turner, G. A. (1996) · Clinical & Experimental Metastasis · doi:10.1007/bf00123391 · Cited by 93
Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation.
Nagy, J. A., Herzberg, K. T., Dvorak, J. M., & Dvorak, H. F. (1993) · PubMed · Cited by 93
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
Hamilton, C. A., Maxwell, G. L., Chernofsky, M. R., Bernstein, S. A., Farley, J. H., & Rose, G. S. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.028 · Cited by 90
Proteomics and biomarkers in clinical trials for drug development
Lee, J., Han, J. J., Altwerger, G. H., & Kohn, E. C. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.04.023 · Cited by 83
Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer
Webb, T. J., Li, X., Giuntoli, R. L., López, P. H. H., Heuser-Loy, C., Schnaar, R. L., Tsuji, M., Kurts, C., Oelke, M., & Schneck, J. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2695 · Cited by 82
Herr, D., Sallmann, A., Bekes, I., Konrad, R., Holzheu, I., Kreienberg, R., & Wulff, C. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.002 · Cited by 79
Ott, M., Marmé, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M. M., Linke, R., & Seimetz, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26258 · Cited by 77
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 75
Mechanisms of malignant ascites production
Garrison, R. N., Galloway, R. H., & Heuser, L. S. (1987) · Journal of Surgical Research · doi:10.1016/0022-4804(87)90109-0 · Cited by 72
Bagnato, A., & Rosanò, L. (2007) · Cells Tissues Organs · doi:10.1159/000101307 · Cited by 69
PATHOGENESIS OF ASCITES IN PERITONEAL CARCINOMATOSIS1
Holm-Nielsen, P. (1953) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1953.tb04805.x · Cited by 68
Goncharenko-Khaider, N., Matte, I., Lane, D. A., Rancourt, C., & Piché, A. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-84 · Cited by 65
Murph, M. M., Liu, W., Yu, S., Lu, Y., Hall, H. S., Hennessy, B. T., Lahad, J. P., Schaner, M. E., Helland, Å., Kristensen, G. B., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005583 · Cited by 64
Elattar, A., Warburton, K. G., Mukhopadhyay, A., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.004 · Cited by 62
Falkenthal, T. E. H., Hellesylt, E., Flørenes, V. A., Trope, C. G., Davidson, B., & Kærn, J. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.10.025 · Cited by 54
Horiuchi, A., Imai, T., 清水, 元., Oka, K., Wang, C., Nikaido, T., & Konishi, I. (2003) · PubMed · Cited by 54
Bellati, F., Napoletano, C., Ruscito, I., Pastore, M., Pernice, M., Antonilli, M., Nuti, M., & Panici, P. B. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9351-4 · Cited by 48
Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions
Gillet, J., Wang, J., Calcagno, A. M., Green, L. J., Varma, S., Elstrand, M. B., Trope, C. G., Ambudkar, S. V., Davidson, B., & Gottesman, M. M. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200240a · Cited by 47
Intraperitoneal interferon in the management of malignant ascites
Stuart, G. C. E., Nation, J. G., Snider, D. D., & Thunberg, P. (1993) · Cancer · Cited by 46
Kryczek, I., Gryboś, M., Karabon, L., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0973 · Cited by 45
Proteomics as a guiding tool for more effective personalized therapy
Lee, J.-M., & Kohn, E. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq375 · Cited by 43
Chen, Y., Gou, X., Ke, X., Cui, H., & Chen, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040965 · Cited by 42
Peart, T. M., Correa, R. J. M., Valdés, Y. R., DiMattia, G. E., & Shepherd, T. G. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9451-3 · Cited by 36
Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells
Schumacher, J. J., Dings, R. P. M., Cosin, J. A., Subramanian, I. V., Auersperg, N., & Ramakrishnan, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3608 · Cited by 36
Autotaxin: Its Role in Biology of Melanoma Cells and as a Pharmacological Target
Jankowski, M. (2011) · Enzyme Research · doi:10.4061/2011/194857 · Cited by 27
Wagner, B. J. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1167 · Cited by 26
Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin
Maiche, A. G. (1994) · Anti-Cancer Drugs · doi:10.1097/00001813-199406000-00007 · Cited by 15
Cited by
Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor
Im, H., Shao, H., Park, Y. I., Peterson, V. M., Castro, C. M., Weissleder, R., & Lee, H. (2014) · Nature Biotechnology · doi:10.1038/nbt.2886 · Cited by 1,321
Technologies and Standardization in Research on Extracellular Vesicles
Gandham, S., Su, X., Wood, J., Nocera, A. L., Alli, S. C., Milane, L., Zimmerman, A., Amiji, M., & Ivanov, A. R. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.05.012 · Cited by 494
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
Song, M., Sandoval, T. A., Chae, C.-S., Chopra, S., Tan, C., Rutkowski, M. R., Raundhal, M., Chaurio, R. A., Payne, K. K., Konrad, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0597-x · Cited by 413
Pospichalova, V., Svoboda, J., Dave, Z., Kotrbova, A., Kaiser, K., Klemova, D., Ilkovics, L., Hampl, A., Crha, I., Jandakova, E., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.25530 · Cited by 387
Metadata
- Authors
- Kipps, E., Tan, D. S. P., & Kaye, S. B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-02-21
- Volume
- 13
- Issue
- 4
- Pages
- 273-282
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2077255241
- Cited by
- 562
- References
- 126
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.